Clinical Trials, Phase II as Topic

"Clinical Trials, Phase II as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.

Descriptor ID	D017322
MeSH Number(s)	E05.318.760.250.500.210 N05.715.360.775.088.500.210 N06.850.520.450.250.250.210
Concept/Terms	Clinical Trials, Phase II as Topic Clinical Trials, Phase II as Topic Evaluation Studies, FDA Phase II as Topic Evaluation Studies, FDA Phase II as Topic Evaluation Studies, FDA Phase 2 as Topic Drug Evaluation, FDA Phase II as Topic Drug Evaluation, FDA Phase II as Topic Drug Evaluation, FDA Phase 2 as Topic

Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase II as Topic".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Epidemiologic Methods [E05.318]
Epidemiologic Study Characteristics [E05.318.760]
Clinical Studies as Topic [E05.318.760.250]
Clinical Trials as Topic [E05.318.760.250.500]
Clinical Trials, Phase II as Topic [E05.318.760.250.500.210]
Health Care [N]
Health Care Quality, Access, and Evaluation [N05]
Quality of Health Care [N05.715]
Health Care Evaluation Mechanisms [N05.715.360]
Epidemiologic Study Characteristics [N05.715.360.775]
Clinical Studies as Topic [N05.715.360.775.088]
Clinical Trials as Topic [N05.715.360.775.088.500]
Clinical Trials, Phase II as Topic [N05.715.360.775.088.500.210]
Environment and Public Health [N06]
Public Health [N06.850]
Epidemiologic Methods [N06.850.520]
Epidemiologic Study Characteristics [N06.850.520.450]
Clinical Studies as Topic [N06.850.520.450.250]
Clinical Trials as Topic [N06.850.520.450.250.250]
Clinical Trials, Phase II as Topic [N06.850.520.450.250.250.210]

Below are MeSH descriptors whose meaning is related to "Clinical Trials, Phase II as Topic".

Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase II as Topic".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Clinical Trials, Phase II as Topic" by people in this website by year, and whether "Clinical Trials, Phase II as Topic" was a major or minor topic of these publications.

Bar chart showing 7 publications over 7 distinct years, with a maximum of 1 publications in 2002 and 2009 and 2016 and 2017 and 2019 and 2020 and 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	0	1	1
2009	1	0	1
2016	0	1	1
2017	0	1	1
2019	0	1	1
2020	0	1	1
2021	0	1	1

Below are the most recent publications written about "Clinical Trials, Phase II as Topic" by people in Profiles.

Alonso-Vega C, Urbina JA, Sanz S, Pinazo MJ, Pinto JJ, Gonzalez VR, Rojas G, Ortiz L, Garcia W, Lozano D, Soy D, Maldonado RA, Nagarkatti R, Debrabant A, Schijman A, Thomas MC, L?pez MC, Michael K, Ribeiro I, Gascon J, Torrico F, Almeida IC. New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia. BMJ Open. 2021 12 31; 11(12):e052897.

View in: PubMed
Hatami E, Jaggi M, Chauhan SC, Yallapu MM. Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics. Biochim Biophys Acta Rev Cancer. 2020 08; 1874(1):188381.

View in: PubMed
Jamil ML, Deebajah M, Sood A, Alanee S. Combination of pembrolizumab and BCG treatment after endoscopic ablation of high-risk superficial upper urinary tract urothelial carcinoma in patients not candidates for radical nephroureterectomy: protocol for phase-II study. BMJ Open. 2019 12 03; 9(12):e027066.

View in: PubMed
Bratincsak A, Limm-Chan BN, Nerurkar VR, Ching LL, Reddy VD, Lim E, Shohet RV, Melish ME. Study design and rationale to assess Doxycycline Efficacy in preventing coronary Artery Lesions in children with Kawasaki disease (DEAL trial) - A phase II clinical trial. Contemp Clin Trials. 2018 02; 65:33-38.

View in: PubMed
Roytman M, Ramkissoon R, Wu C, Hong L, Trujillo R, Huddleston L, Poerzgen P, Seto T, Wong L, Tsai N. Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestry. Hepatol Int. 2016 Jul; 10(4):616-23.

View in: PubMed
Lammers PE, Horn L. Targeting angiogenesis in advanced non-small cell lung cancer. J Natl Compr Canc Netw. 2013 Oct 01; 11(10):1235-47.

View in: PubMed
Issell BF, Gotay CC, Pagano I, Franke AA. Using quality of life measures in a Phase I clinical trial of noni in patients with advanced cancer to select a Phase II dose. J Diet Suppl. 2009; 6(4):347-59.

View in: PubMed
Hawes D, Liu PY, Muggia FM, Wilczynski S, Cote R, Felix J, Terada K, Belt RJ, Alberts DS. Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study. Gynecol Oncol. 2002 Oct; 87(1):17-23.

View in: PubMed
Wang WC, Helms RW, Lynn HS, Redding-Lallinger R, Gee BE, Ohene-Frempong K, Smith-Whitley K, Waclawiw MA, Vichinsky EP, Styles LA, Ware RE, Kinney TR. Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. J Pediatr. 2002 Feb; 140(2):225-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals